Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Iq-ai Ltd (IQAI)

Price 1.60p on 26-04-2024 at 16:30:01
Change 0.05p 3.23%
Buy 1.70p
Sell 1.50p
Buy / Sell IQAI Shares
Last Trade: Buy 197.00 at 1.70p
Day's Volume: 21,122
Last Close: 1.60p
Open: 1.55p
ISIN: JE00BD4H0R42
Day's Range 1.55p - 1.60p
52wk Range: 1.27p - 5.75p
Market Capitalisation: £4m
VWAP: 1.566944p
Shares in Issue: 222m

Recent Trades History Iq-ai Ltd (IQAI)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 197 1.70p SI Trade
15:29:39 - 26-Apr-24
Buy* 11,812 1.60p Ordinary
15:29:35 - 26-Apr-24
Buy* 93 1.60p SI Trade
14:04:38 - 26-Apr-24
Sell* 5,000 1.5161p Ordinary
11:48:41 - 26-Apr-24
Sell* 66 1.50p SI Trade
09:02:10 - 26-Apr-24
Buy* 179 1.60p SI Trade
07:21:06 - 26-Apr-24
Buy* 136 1.60p SI Trade
07:21:06 - 26-Apr-24
Buy* 125 1.60p SI Trade
07:21:06 - 26-Apr-24
Sell* 1,333 1.50p SI Trade
07:21:06 - 26-Apr-24
Sell* 145 1.50p SI Trade
07:21:06 - 26-Apr-24

Share Price History for Iq-ai Ltd

Time period:
to
Date Open High Low Close Volume

Share News for Iq-ai Ltd

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

22nd Feb 2024 14:02

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1. Read More

IQ-AI subsidiary asked by FDA to resubmit and modify application

9th Feb 2024 13:38

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration. Read More

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

2nd Feb 2024 08:56

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding. Read More

IQ-AI falls after subsidiary notes launch of treatment access scheme

10th Jan 2024 11:48

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate. Read More

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

19th Dec 2023 17:00

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma. Read More

FTSE 100 Latest
Value8,139.83
Change60.97

Login to your account

Forgot Password?

Not Registered